Host Maddie Mossman talks with Dr. Daniel Chung, Chief Medical Officer of Beacon Therapeutics, about Laru-zova, an emerging treatment for X-linked retinitis pigmentosa. Based on encouraging clinical trial results, Beacon plans to begin a rolling FDA submission for the potential gene therapy later this year. The Foundation funded pre-clinical research that went on to became laru-zova.